<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03960000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P53350</UniProt_ID>
  <Seq_Length>603</Seq_Length>
  <Molecule_Weight>68255</Molecule_Weight>
  <KEGG_ID>hsa:5347</KEGG_ID>
  <Orthology_ID>K06631</Orthology_ID>
  <EBI_ID>EBI-476768</EBI_ID>
  <Function_Summary>Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis. Polo-like kinase proteins acts by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates BORA, BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1, KIF20A/MKLP2, MLF1IP, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, PLK1S1/KIZ, PPP1R12A/MYPT1, PRC1, RACGAP1/CYK4, SGOL1, STAG2/SA2, TEX14, TOPORS, p73/TP73, TPT1 and WEE1. Plays a key role in centrosome functions and the assembly of bipolar spindles by phosphorylating PLK1S1/KIZ, NEDD1 and NINL. NEDD1 phosphorylation promotes subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. Phosphorylation of NINL component of the centrosome leads to NINL dissociation from other centrosomal proteins. Involved in mitosis exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2, MLF1IP, PRC1 and RACGAP1. Recruited at the central spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own docking sites on PRC1 and KIF20A/MKLP2 by mediating phosphorylation of sites subsequently recognized by the POLO box domains. Phosphorylates RACGAP1, thereby creating a docking site for the Rho GTP exchange factor ECT2 that is essential for the cleavage furrow formation. Promotes the central spindle recruitment of ECT2. Plays a central role in G2/M transition of mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, MLF1IP, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1. Part of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the positive regulator CDC25C and inhibiting the negative regulators WEE1 and PKMYT1/MYT1. Also acts by mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in prophase. Phosphorylates FOXM1, a key mitotic transcription regulator, leading to enhance FOXM1 transcriptional activity. Involved in kinetochore functions and sister chromatide cohesion by phosphorylating BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2. PLK1 is high on non-attached kinetochores suggesting a role of PLK1 in kinetochore attachment or in spindle assembly checkpoint (SAC) regulation. Required for kinetochore localization of BUB1B. Regulates the dissociation of cohesin from chromosomes by phosphorylating cohesin subunits such as STAG2/SA2. Phosphorylates SGOL1: required for spindle pole localization of isoform 3 of SGOL1 and plays a role in regulating its centriole cohesion function. Mediates phosphorylation of FBXO5/EMI1, a negative regulator of the APC/C complex during prophase, leading to FBXO5/EMI1 ubiquitination and degradation by the proteasome. Acts as a negative regulator of p53 family members: phosphorylates TOPORS, leading to inhibit the sumoylation of p53/TP53 and simultaneously enhance the ubiquitination and subsequent degradation of p53/TP53. Phosphorylates the transactivation domain of the transcription factor p73/TP73, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the degradation of BORA. Contributes to the regulation of AURKA function. Also required for recovery after DNA damage checkpoint and entry into mitosis.</Function_Summary>
  <Catalytic_Mechanism>ATP + a protein = ADP + a phosphoprotein.</Catalytic_Mechanism>
  <Pfam_ID>PF00069:Pkinase@@PF00659:POLO_box</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>PLK-1</Alias>
      <Alias>STPK13</Alias>
      <Alias>Serine/threonine-protein kinase 13</Alias>
      <Alias>Polo-like kinase 1</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate.</Detail>
      <Keyword>Protein kinase binding</Keyword>
      <Ontology_ID>GO:0019901</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with microtubules, filaments composed of tubulin monomers.</Detail>
      <Keyword>Microtubule binding</Keyword>
      <Ontology_ID>GO:0008017</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an anaphase-promoting complex. A ubiquitin ligase complex that degrades mitotic cyclins and anaphase inhibitory protein, thereby triggering sister chromatid separation and exit from mitosis.</Detail>
      <Keyword>Anaphase-promoting complex binding</Keyword>
      <Ontology_ID>GO:0010997</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.</Detail>
      <Keyword>Protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0004674</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>297</Position>
      <Original>Asn</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>261</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>595</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>599</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>332</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>463</Position>
      <Original>Leu</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>518</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>12</Position>
      <Original>Arg</Original>
      <Variation>Leu</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that initiates the ubiquitin ligase activity of the anaphase-promoting complex that regulates the mitotic metaphase/anaphase transition.</Detail>
      <Keyword>Activation of mitotic anaphase-promoting complex activity</Keyword>
      <Ontology_ID>GO:0007092</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a centrosome, a structure comprised of a pair of centrioles and peri-centriolar material from which a microtubule spindle apparatus is organized.</Detail>
      <Keyword>Centrosome organization</Keyword>
      <Ontology_ID>GO:0051297</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that results in a parallel arrangement of microtubules.</Detail>
      <Keyword>Microtubule bundle formation</Keyword>
      <Ontology_ID>GO:0001578</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The multiplication or reproduction of cells, resulting in the expansion of a cell population.</Detail>
      <Keyword>Cell proliferation</Keyword>
      <Ontology_ID>GO:0008283</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cell cycle checkpoint that blocks cell cycle progression from G2 to M phase in response to DNA damage.</Detail>
      <Keyword>G2/M transition DNA damage checkpoint</Keyword>
      <Ontology_ID>GO:0031572</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cell cycle process in which a cell progresses from metaphase to anaphase during mitosis, triggered by the destruction of mitotic cyclins.</Detail>
      <Keyword>Mitotic metaphase/anaphase transition</Keyword>
      <Ontology_ID>GO:0007091</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process resulting in the physical partitioning and separation of a cell into daughter cells.</Detail>
      <Keyword>Cell division</Keyword>
      <Ontology_ID>GO:0051301</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency, rate or extent of peptidyl-threonine phosphorylation. Peptidyl-threonine phosphorylation is the phosphorylation of peptidyl-threonine to form peptidyl-O-phospho-L-threonine.</Detail>
      <Keyword>Positive regulation of peptidyl-threonine phosphorylation</Keyword>
      <Ontology_ID>GO:0010800</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by the anaphase-promoting complex, and mediated by the proteasome.</Detail>
      <Keyword>Anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process</Keyword>
      <Ontology_ID>GO:0031145</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Progression from G2 phase to M phase of the mitotic cell cycle.</Detail>
      <Keyword>G2/M transition of mitotic cell cycle</Keyword>
      <Ontology_ID>GO:0000086</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cell cycle process comprising the steps by which the nucleus of a eukaryotic cell divides; the process involves condensation of chromosomal DNA into a highly compacted form. Canonically, mitosis produces two daughter nuclei whose chromosome complement is identical to that of the mother cell.</Detail>
      <Keyword>Mitosis</Keyword>
      <Ontology_ID>GO:0007067</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which a protein is transported to, or maintained at, a part of a chromosome that is organized into chromatin.</Detail>
      <Keyword>Protein localization to chromatin</Keyword>
      <Ontology_ID>GO:0071168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation of peptidyl-serine to form peptidyl-O-phospho-L-serine.</Detail>
      <Keyword>Peptidyl-serine phosphorylation</Keyword>
      <Ontology_ID>GO:0018105</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division.</Detail>
      <Keyword>Cell cycle</Keyword>
      <Ontology_ID>GO:0007049</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the stability of a protein, making it more vulnerable to degradative processes or aggregation.</Detail>
      <Keyword>Protein destabilization</Keyword>
      <Ontology_ID>GO:0031648</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of protein binding.</Detail>
      <Keyword>Regulation of protein binding</Keyword>
      <Ontology_ID>GO:0043393</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of CDK activity.</Detail>
      <Keyword>Negative regulation of cyclin-dependent protein kinase activity</Keyword>
      <Ontology_ID>GO:0045736</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which one or more ubiquitin groups are added to a protein.</Detail>
      <Keyword>Protein ubiquitination</Keyword>
      <Ontology_ID>GO:0016567</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Prophase occurring as part of mitosis. Prophase is the part of nuclear division in which, canonically, chromosomes condense and the two daughter centrioles and their asters migrate toward the poles of the cell. Mitosis is the cell cycle process in which, canonically, the nucleus of a eukaryotic cell divides to produce two daughter nuclei whose chromosome complement is identical to that of the mother cell.</Detail>
      <Keyword>Mitotic prophase</Keyword>
      <Ontology_ID>GO:0000088</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of mitotic anaphase, a cell cycle process comprising the steps by which a cell progresses through anaphase, the stage of mitosis during which the two sets of chromosomes separate and move away from each other.</Detail>
      <Keyword>Regulation of mitotic anaphase</Keyword>
      <Ontology_ID>GO:0090007</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cell cycle process comprising the steps by which a cell progresses through prometaphase, the stage following prophase in mitosis (in higher eukaryotes) during which the nuclear envelope is disrupted and breaks into membrane vesicles, and the spindle microtubules enter the nuclear region. Kinetochores mature on each centromere and attach to some of the spindle microtubules. Kinetochore microtubules begin the process of aligning chromosomes in one plane halfway between the poles.</Detail>
      <Keyword>Mitotic prometaphase</Keyword>
      <Ontology_ID>GO:0000236</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>137</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>210</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>103</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>269</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>498</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>335</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>461</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>214</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>464</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>375</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>450</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>6</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MSAAVTAGKLARAPADPGKAGVPGVAAPGAPAAAPPAKEIPEVLVDPRSRRRYVRGRFLGKGGFAKCFEISDADTKEVFAGKIVPKSLLLKPHQREKMSMEISIHRSLAHQHVVGFHGFFEDNDFVFVVLELCRRRSLLELHKRRKALTEPEARYYLRQIVLGCQYLHRNRVIHRDLKLGNLFLNEDLEVKIGDFGLATKVEYDGERKKTLCGTPNYIAPEVLSKKGHSFEVDVWSIGCIMYTLLVGKPPFETSCLKETYLRIKKNEYSIPKHINPVAASLIQKMLQTDPTARPTINELLNDEFFTSGYIPARLPITCLTIPPRFSIAPSSLDPSNRKPLTVLNKGLENPLPERPREKEEPVVRETGEVVDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS</Protein_Seq>
    <DNA_Seq>GGGAGGAGCGGAGAGGTGCGGAGCCTCTACTGGGATCCACGTCTGCTGAGCAGCTCCAGGAACATGACTGCAGCGGTGACTGCGGGGAAGCTGCCACGGGCACCGGCCGACCCTGGGAAAGCCGGGGTCCCCGGAGTTGCAGCTCCCGGAGCTCCGGCGGCGGCTCCACCGGCGAAAGAGATCCCGGAGGTCCTAGTGGACCCACGCAGCCGGCGGCGCTATGTGCGGGGCCGCCTTTTGAGCAAGGGCGGCTTTGCCAAGTGCTTCGAGATCTCGGACGCGGACACCAAGGAGGTGTTCGCGGGCAAGATTGTGCCTAAGTCTCTGCTGCTCAAGCCGCACCAGAGGGAGAAGATGTCCATGGAAATATCCATTCACCGCAGCCTCGCCCACCAGCACGTCGTAGGATTCCACGGCTTTTTCGAGGACAACGACTTCGTGTTCGTGGTGTTGGAGCTCTGCCGCCGGAGGTCTCTCCTGGAGCTGCACAAGAGGAGGAAAGCCCTGACTGAGCCTGAGGCCCGATACTACCTACGGCAAATTGTGCTTGGCTGCCAGTACCTGCACCGAAACCGAGTTATTCATCGAGACCTCAAGCTGGGCAACCTTTTCCTGAATGAAGATCTGGAGGTGAAAATAGGGGATTTTGGACTGGCAACCAAAGTCGAATATGACGGGGAGAGGAAGAAGACCCTGTGTGGGACTCCTAATTACATAGCTCCCGAGGTGCTGAGCAAGAAAGGGCACAGTTTCGAGGTGGATGTGTGGTCCATTGGGTGTATCATGTATACCTTGTTAGTGGGCAAACCACCTTTTGAGACTTCTTGCCTAAAAGAGACCTACCTCCGGATCAAGAAGAATGAATACAGTATTCCCAAGCACATCAACCCCGTGGCCGCCTCCCTCATCCAGAAGATGCTTCAGACAGATCCCACTGCCCGCCCAACCATTAACGAGCTGCTTAATGACGAGTTCTTTACTTCTGGCTATATCCCTGCCCGTCTCCCCATCACCTGCCTGACCATTCCACCAAGGTTTTCGATTGCTCCCAGCAGCCTGGACCCCAGCAACCGGAAGCCCCTCACAGTCCTCAATAAAGGCTTGGAGAACCCCCTGCCTGAGCGTCCCCGGGAAAAAGAAGAACCAGTGGTTCGAGAGACAGGTGAGGTGGTCGACTGCCACCTCAGTGACATGCTGCAGCAACTGCACAGTGTCAATGCCTCCAAGCCCTCGGAGCGTGGGCTGGTCAGGCAAGAGGAGGCTGAGGATCCTGCCTGCATCCCCATCTTCTGGGTCAGCAAGTGGGTGGACTATTCGGACAAGTACGGCCTTGGGTATCAGCTCTGTGATAACAGCGTGGGGGTGCTCTTCAATGACTCAACACGCCTCATCCTCTACAATGATGGTGACAGCCTGCAGTACATAGAGCGTGACGGCACTGAGTCCTACCTCACCGTGAGTTCCCATCCCAACTCCTTGATGAAGAAGATCACCCTCCTTAAATATTTCCGCAATTACATGAGCGAGCACTTGCTGAAGGCAGGTGCCAACATCACGCCGCGCGAAGGTGATGAGCTCGCCCGGCTGCCCTACCTACGGACCTGGTTCCGCACCCGCAGCGCCATCATCCTGCACCTCAGCAACGGCAGCGTGCAGATCAACTTCTTCCAGGATCACACCAAGCTCATCTTGTGCCCACTGATGGCAGCCGTGACCTACATCGACGAGAAGCGGGACTTCCGCACATACCGCCTGAGTCTCCTGGAGGAGTACGGCTGCTGCAAGGAGCTGGCCAGCCGGCTCCGCTACGCCCGCACTATGGTGGACAAGCTGCTGAGCTCACGCTCGGCCAGCAACCGTCTCAAGGCCTCCTAATAGCTGCCCTCCCCTCCGGACTGGTGCCCTCCTCACTCCCACCTGCATCTGGGGCCCATACTGGTTGGCTCCCGCGGTGCCATGTCTGCAGTGTGCCCCCCAGCCCCGGTGGCTGGGCAGAGCTGCATCATCCTTGCAGGTGGGGGTTGCTGTATAAGTTATTTTTGTACATGTTCGGGTGTGGGTTCTACAGCCTTGTCCCCCTCCCCCTCAACCCCACCATATGAATTGTACAGAATATTTCTATTGAATTCGGAACTGTCCTTTCCTTGGCTTTATGCACATTAAACAGATGTGAATATTAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Placenta</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Colon</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Centrosome</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Kinetochore</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>PLK1</Gene_Name>
    <Gene_Alias>PLK</Gene_Alias>
    <Gene_ID>5347</Gene_ID>
    <Genbank_ACCN>NM_005030</Genbank_ACCN>
    <Protein_ACCN>NP_005021</Protein_ACCN>
    <HGNC_ID>9077</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5347</Gene_URL>
    <UCSC_ID>uc002dlz.1</UCSC_ID>
    <EMBL_ID>ENSG00000166851</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P08107</Uniprot_ID>
      <Gene_Name>HSPA1B</Gene_Name>
      <EBI_ID>EBI-629985</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-629985</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O75665</Uniprot_ID>
      <Gene_Name>OFD1</Gene_Name>
      <EBI_ID>EBI-716327</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-716327</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8IXK0</Uniprot_ID>
      <Gene_Name>PHC2</Gene_Name>
      <EBI_ID>EBI-713786</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-713786</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9NR09</Uniprot_ID>
      <Gene_Name>BIRC6</Gene_Name>
      <EBI_ID>EBI-1765160</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-1765160</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q92844</Uniprot_ID>
      <Gene_Name>TANK</Gene_Name>
      <EBI_ID>EBI-356349</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-356349</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O96017</Uniprot_ID>
      <Gene_Name>CHEK2</Gene_Name>
      <EBI_ID>EBI-1180783</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-1180783</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P33993</Uniprot_ID>
      <Gene_Name>MCM7</Gene_Name>
      <EBI_ID>EBI-355924</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-355924</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8IY92</Uniprot_ID>
      <Gene_Name>SLX4</Gene_Name>
      <EBI_ID>EBI-2370740</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-2370740</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P23588</Uniprot_ID>
      <Gene_Name>EIF4B</Gene_Name>
      <EBI_ID>EBI-970310</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-970310</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q13158</Uniprot_ID>
      <Gene_Name>FADD</Gene_Name>
      <EBI_ID>EBI-494804</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-494804</PPI_EBI_URL>
      <Experiment_Number>9</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O60447</Uniprot_ID>
      <Gene_Name>EVI5</Gene_Name>
      <EBI_ID>EBI-852291</EBI_ID>
      <PPI_EBI_URL>EBI-476768,EBI-852291</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Tetraploidy</Disease_Name>
      <Disease_Detail>Tetraploidy</Disease_Detail>
      <Disease_DB>TTR011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tetraploidy?search=PLK1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization</PDB_Title>
      <PDB_ID>3BZI</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BZI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>FORMIC ACID</Ligand_Name>
      <PubMed_Title>Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.</PubMed_Title>
      <PubMed_ID>17307877</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization</PDB_Title>
      <PDB_ID>2OJX</PDB_ID>
      <Resolution>2.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OJX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.</PubMed_Title>
      <PubMed_ID>17307877</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The polo-box domain of Plk1 in complex with a phospho-peptide</PDB_Title>
      <PDB_ID>1Q4K</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q4K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex.</PubMed_Title>
      <Author>Cheng KY, et al.</Author>
      <Journal>EMBO J.2003 Nov 3;22(21):5757-68.</Journal>
      <PubMed_ID>14592974</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF A HUMAN PLK1 POLO-BOX DOMAIN/PHOSPHOPEPTIDE COMPLEX</PDB_Title>
      <PDB_ID>1UMW</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UMW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Plks by the Polo-Box Domain</PubMed_Title>
      <Author>Elia AE, et al.</Author>
      <Journal>Cell.2003 Oct 3;115(1):83-95.</Journal>
      <PubMed_ID>14532005</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of the Catalytic Domain of Human Polo-like Kinase 1</PDB_Title>
      <PDB_ID>2OU7</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OU7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER</Ligand_Name>
      <PubMed_Title>Structure of the catalytic domain of human polo-like kinase 1.</PubMed_Title>
      <Author>Kothe M, et al.</Author>
      <Journal>Biochemistry.2007 May 22;46(20):5960-71. Epub  2007 Apr 27.</Journal>
      <PubMed_ID>17461553</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human Plk1-PBD with glycerol and sulfate in the phophopeptide binding site</PDB_Title>
      <PDB_ID>3HIH</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HIH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL$GLYCEROL</Ligand_Name>
      <PubMed_Title>Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.</PubMed_Title>
      <Author>Yun SM, et al.</Author>
      <Journal>Nat Struct Mol Biol.2009 Aug;16(8):876-82. Epub  2009 Jul 13.</Journal>
      <PubMed_ID>19597481</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Polo-like kinase 1 Polo box domain in complex with Ac-LHSpTA-NH2 peptide</PDB_Title>
      <PDB_ID>3FVH</PDB_ID>
      <Resolution>1.58</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FVH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1</PubMed_Title>
      <Author>Yun SM, et al.</Author>
      <Journal>Nat Struct Mol Biol.2009 Aug;16(8):876-82. Epub  2009 Jul 13.</Journal>
      <PubMed_ID>19597481</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PLK1 in complex with BI6727</PDB_Title>
      <PDB_ID>3FC2</PDB_ID>
      <Resolution>2.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FC2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-{trans-4-[4-(cyclopropylmethyl)piperazin- 1-yl]cyclohexyl}-4-{[(7R)-7-ethyl-5
-methyl- 8-(1-methylethyl)-6-oxo-5,6,7,8-tetrahydropteridin- 2-yl]amino}-3
-methoxybenzamide</Ligand_Name>
      <PubMed_Title>BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity.</PubMed_Title>
      <Author>Rudolph D, et al.</Author>
      <Journal>Clin Cancer Res.2009 May 1;15(9):3094-102. Epub  2009 Apr 21.</Journal>
      <PubMed_ID>19383823</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Polo-like kinase 1 Polo box domain in complex with PPHSpT peptide</PDB_Title>
      <PDB_ID>3C5L</PDB_ID>
      <Resolution>2.33</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3C5L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.</PubMed_Title>
      <Author>Yun SM, et al.</Author>
      <Journal>Nat Struct Mol Biol.2009 Aug;16(8):876-82. Epub  2009 Jul 13.</Journal>
      <PubMed_ID>19597481</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of the polo box domain of human Plk1</PDB_Title>
      <PDB_ID>1Q4O</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q4O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex.</PubMed_Title>
      <Author>Cheng KY, et al.</Author>
      <Journal>EMBO J.2003 Nov 3;22(21):5757-68.</Journal>
      <PubMed_ID>14592974</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN</PDB_Title>
      <PDB_ID>2V5Q</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2V5Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure Pf Wild-Type Plk-1 Kinase Domain in Complex with a Selective Darpin</PubMed_Title>
      <Author>Bandeiras TM, et al.</Author>
      <Journal>Acta Crystallogr D Biol Crystallogr.2008 Apr;64(Pt 4):339-53. Epub  2008 Mar 19.</Journal>
      <PubMed_ID>18391401</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of the Catalytic Domain of Human Polo-like Kinase 1</PDB_Title>
      <PDB_ID>2OWB</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OWB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)- 1,5-DIHYDROPYRROLO[3,4
-C]PYRAZOL-3-YL]BENZAMIDE</Ligand_Name>
      <PubMed_Title>Structure of the catalytic domain of human polo-like kinase 1.</PubMed_Title>
      <Author>Kothe M, et al.</Author>
      <Journal>Biochemistry.2007 May 22;46(20):5960-71. Epub  2007 Apr 27.</Journal>
      <PubMed_ID>17461553</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Molecular and structural basis of Plk1 substrate recognition: Implications in centrosomal localization</PDB_Title>
      <PDB_ID>2OGQ</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OGQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.</PubMed_Title>
      <PubMed_ID>17307877</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human Plk1-PBD in complex with PLHSpT</PDB_Title>
      <PDB_ID>3HIK</PDB_ID>
      <Resolution>1.77</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HIK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL$GLYCEROL</Ligand_Name>
      <PubMed_Title>Structural and functional analyses of a minimal phosphopeptide targeting the polo-box domain of mammalian polo-like kinase 1</PubMed_Title>
      <Author>Yun SM, et al.</Author>
      <Journal>To be published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of PLK1 in complex with BI2536</PDB_Title>
      <PDB_ID>2RKU</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2RKU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6- oxo-5,6,7,8-tetrahydropteridin-2
-yl]amino}- 3-methoxy-N-(1-methylpiperidin-4-yl)benzamide$S,R MESO-TARTARIC ACID $D(-)-TARTARIC ACID $L(+)-TARTARIC ACID</Ligand_Name>
      <PubMed_Title>Selectivity-determining residues in Plk1.</PubMed_Title>
      <Author>Kothe M, et al.</Author>
      <Journal>Chem Biol Drug Des.2007 Dec;70(6):540-6. Epub  2007 Nov 13.</Journal>
      <PubMed_ID>18005335</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04114</Pathway_ID>
      <Pathway_Title>Oocyte meiosis</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04914</Pathway_ID>
      <Pathway_Title>Progesterone-mediated oocyte maturation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04114</Pathway_ID>
      <Pathway_Title>Oocyte meiosis</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04110</Pathway_ID>
      <Pathway_Title>Cell cycle</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04068</Pathway_ID>
      <Pathway_Title>FoxO signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04114</Pathway_ID>
      <Pathway_Title>Oocyte meiosis</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.gh.b.b.b.html</SCOP_URL>
    <CATH_Class>Mixed alpha-beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1q4k</CATH_URL>
  </Fold>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.11.21</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/11/21.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>